Lutetium-177 (Lu-177) Market, Global Outlook and Forecast 2025-2032
Lutetium-177 (Lu-177) Market, Global Outlook and Forecast 20252032
Comprehensive insight into regional dynamics, growth drivers, and market segmentation.
MARKET OVERVIEW:
Lutetium-177 is a radioactive isotope widely used in targeted radionuclide therapy for cancer treatment. With a half-life of 6.6 days, it emits both beta and gamma radiation, making it ideal for both therapeutic and diagnostic applications (theranostics). The isotope is primarily utilized in treating neuroendocrine tumors (NETs) and prostate cancer through PSMA-targeted therapies, offering precision treatment with minimal damage to surrounding healthy tissues.
MARKET INSIGHT & GROWTH DRIVERS:
The market growth is driven by increasing gold mining activities, particularly in Asia-Pacific and Africa, where cyanide leaching remains the dominant extraction method. However, environmental concerns and stringent regulations pose challenges to market expansion.
MARKET SEGMENTATION:
MARKET DYNAMICS
Growing Pharmaceutical Applications Fuel Demand for (S)-Glycidol
The rising global incidence of neuroendocrine tumors (NETs) and prostate cancer is driving significant demand for Lu-177 based therapies. With prostate cancer cases projected to exceed 2.9 million globally by 2025 and NET diagnoses increasing at an annual rate of 6%, the need for targeted radionuclide therapies has never been greater. Lu-177 PSMA therapy has demonstrated remarkable efficacy in clinical trials, showing tumor response rates exceeding 60% in metastatic castration-resistant prostate cancer patients. This strong clinical validation, combined with the growing cancer burden, creates substantial momentum for market growth.
MARKET OPPORTUNITIES
The development of Lu-177 combination regimens represents a significant market opportunity. Clinical trials exploring Lu-177 with immune checkpoint inhibitors, PARP inhibitors, and targeted therapies are showing promising synergy. Early-phase studies in prostate cancer demonstrate that combining Lu-177 PSMA with pembrolizumab can increase progression-free survival by an additional 4-6 months compared to monotherapy. Such combination approaches could expand eligible patient populations while potentially commanding premium pricing, driving market value beyond current projections.
COMPANY MISSION
Despite growing demand, the market faces supply chain bottlenecks in Lu-177 production.
The isotope's 6.6-day half-life necessitates sophisticated logistics and regional production hubs, with current global capacity estimated at only 40,000 doses annually. However, technological breakthroughs in neutron capture methods and the emergence of particle accelerator-based production by companies like SHINE Technologies are beginning to alleviate shortages. Investment in production facilities has increased by 32% since 2023, with several new reactors and cyclotron facilities expected to come online by 2026, potentially doubling global
REGIONAL MARKET OUTLOOK
North America
North America dominates the global Lutetium-177 market, accounting for 34% of total revenue in 2024. The region's leadership stems from advanced nuclear medicine infrastructure, high healthcare expenditure, and rapid adoption of radiopharmaceutical therapies.
Europe
Europe maintains the second-largest market share for Lutetium-177 therapies, driven by universal healthcare systems that facilitate patient access to advanced treatments. The region has pioneered regulatory frameworks for radiopharmaceuticals through EMA guidance, supporting standardized treatment protocols across member states.
These companies represent some of the major key players driving innovation and growth in the market, contributing significantly to global supply and competitive dynamics.
About Us
Founded in 2015, 24chemicalresearch is a trusted name in global chemical industry intelligence. We specialize in delivering high-quality market research reports, empowering over 30+ Fortune 500 clients with data-driven insights for strategic growth. Our team of experienced analysts delivers customized, reliable, and timely research backed by a rigorous methodology. From mining regulatory trends to forecasting market opportunities, our reports help companies navigate industry challenges, stay competitive, and grow confidently.
As a one-stop platform for the chemical sector, we offer:
• Deep specialization in chemical market analysis
• Customized reports tailored to your needs
• A robust portal with free samples, consulting, and competitive insights
